

PRESS RELEASE

Dresden, Germany – November 8th, 2004 - The Genetics Company, Inc. a privately held Swiss company focusing on the research, development and commercialization of products for the diagnosis, monitoring and therapy of patients suffering from Alzheimer's disease and cancer will open their second German Alzheimer's disease reference center in Dresden, Germany in cooperation with the medical laboratory Laborpraxis Dr. Zimmermann / Dr. Piontek / Dr. Bochmann Dresden. The inauguration is to be held in Dresden on the 10th November 2004 and will be accompanied by vocational training for local doctors and clinicians focusing on the diagnosis and therapy of Alzheimer's disease. Speakers include well known Alzheimer's disease and cerebrospinal fluid (CSF) diagnostics researchers PD Dr. H. Tumani, Prof. Dr. J. Wiltfang and CA Dr. Ficker.

The medical laboratory Laborpraxis Dr. Zimmermann / Dr. Piontek / Dr. Bochmann Dresden already offer a wide range of high quality analyses, including CSF diagnostics for a large variety of different conditions and diseases. As of November, the Laborpraxis Dr. Zimmermann / Dr. Piontek / Dr. Bochmann Dresden will function as the central reference center for Saxony by analyzing patient CSF-samples from suspected Alzheimer's disease patients from surrounding clinics and general practitioners. The Genetics Company will supply the Laborpraxis Dr. Zimmermann / Dr. Piontek / Dr. Bochmann with its innovative, CE-certified Amyloid beta (Abeta) 40/42 test kits for the detection of Alzheimer's disease specific peptides in human CSF samples. The Genetics Company's Abeta 40 and Abeta 42 test kits facilitate the determination of the Abeta-ratio, which is believed to be the most sensitive biochemical Alzheimer's disease diagnostic method currently available. Early stage Alzheimer's disease patients can be identified using this Abeta-ratio thus assisting therapeutic treatment and associated palliative measures.

This Alzheimer's disease reference center in Dresden is however one of many reference centers, which The Genetics Company will be opening in the coming months throughout Germany, followed by the rest of Europe. A reference center already exists at the Medizinisches Labor Bremen, Germany and the next reference center to open will be at Ulm University, Germany in early 2005.

Dr. Zimmermann of the Laborpraxis Dr. Zimmermann / Dr. Piontek / Dr. Bochmann Dresden was quoted as saying "We are delighted to be able to include the Abeta-ratio into our wide range of analyses as it will permit us to significantly optimize our diagnostic ability for Alzheimer's disease and to meet the ever increasing demand for such tests. These tests will allow us to significantly optimize the diagnosis process of potential Alzheimer's disease patients and therefore enable us to supply important diagnostic information to the doctors especially in early stages of the disease". Whereas, Dr. Harald Eistetter, CEO of The Genetics Company, adding the following comments "The Laborpraxis Dr. Zimmermann / Dr. Piontek / Dr. Bochmann Dresden have an excellent reputation, especially for CSF analyses where they are perceived to be among the best at a national level. We are very pleased that they will operate as our second reference center in Germany for our Abeta 40/42 CSF test kits".

About the Laborpraxis Zimmermann und Piontek Dresden

The medical laboratory Laborpraxis Dr. Zimmermann / Dr. Piontek / Dr. Bochmann Dresden and their partners Privatlabor Dr. Schierz / DC Bauer offer a complete spectrum of diagnostic measurements for local general practitioners, midwives, traditional healers and hospitals. These measurements are conducted to the highest quality specifications as illustrated by their DIN EN ISO/IEC 17025 certification from the German Chemistry Accreditation Body (Deutsche Akkreditierungsstelle Chemie). The laboratory's area of expertise is CSF analyses, where they offer a range of measurements such as cytology, protein, pathogen, dementia and polymerase chain reaction (PCR) among others. This expertise is clearly exemplified by their status as a CSF diagnostic vocational training laboratory for both the German Society for CSF Diagnostic (Deutsche Gesellschaft für Liquordiagnostik) and the German Clinical Neurochemistry Registered Association (Klinische Neurochemie e.V.); a status achieved by only few medical laboratories.

About The Genetics Company, Inc.

The Genetics Company, Inc. is a dedicated team of entrepreneurs and scientists focusing on the research, development and commercialization of innovative products for the diagnosis, therapy and treatment monitoring of patients suffering from neurodegenerative diseases and cancer. Apart from a set of worldwide unique diagnostic kits and tools for the diagnosis and monitoring of patients suffering from Alzheimer's disease (AD), the Company has identified small molecule inhibitors of BACE (beta-amyloid converting enzyme) for use in the treatment of Alzheimer's disease. It has also identified small molecule inhibitors of two proprietary targets within the Wnt-pathway, which is believed to play a crucial role in colon cancer. In parallel, the Company has identified and is in the process of further characterizing novel growth-related drug target candidate genes and potential growth-related small molecules for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the Company currently has 30 employees.

For additional information about the Laborpraxis Zimmermann und Piontek Dresden please contact:

Dr. Klaus Zimmermann

Laborpraxis Dr. Zimmermann / Dr. Piontek / Dr. Bochmann Dresden

Wurzener Strasse 5

01127 Dresden

Germany

Tel: +49-351-8522256

Fax: +49-351-8522255

E-mail: k.zimmermann@labor-dresden-elsterwerda.de

Web: www.labor-dresden-elsterwerda.de

For additional information about the Genetics Company and its Alzheimer's diagnostics products, please contact:

*Dr. Harald Eistetter
The Genetics Company
Wagistrasse 27
CH-8952 Schlieren/Zürich
Switzerland
Tel: +41-44-2002222
Fax: +41-44-2002211
E-mail: eistetter@the-genetics.com
Web: www.the-genetics.com*

08.11.2004 / 4,669 characters (without spaces)